Institute of Medical Psychology & Behavioral Immunobiology, University Hospital Essen, University of Duisburg-Essen, Germany.
Clinic for Trauma and Orthopedic Surgery, University Hospital Essen, University of Duisburg-Essen, Germany.
Clin Pharmacol Ther. 2017 Jul;102(1):141-151. doi: 10.1002/cpt.618. Epub 2017 Mar 25.
We aimed to identify statistical predictor variables of lipopolysaccharide (LPS)-induced physical sickness symptoms during the acute and late inflammatory phases using multivariate regression analyses. Data from N = 128 healthy volunteers who received i.v. LPS injection (0.4 or 0.8 ng/kg) or placebo were pooled for analyses. Physical sickness symptoms experienced during the acute (0-6h postinjection) and late (6-24h postinjection) phases were assessed with the validated General-Assessment-of-Side-Effects (GASE) questionnaire. LPS-treated subjects reported significantly more physical sickness symptoms. Physical symptoms during the acute phase were associated with LPS-induced mood impairments and interleukin (IL)-6 increases, explaining 28.5% of variance in GASE scores. During late phase, LPS-induced increases in cortisol and IL-6 plasma concentrations and baseline depression were significant predictor variables, explaining 38.5% of variance. In patients with recurrent or chronic inflammatory states, these factors may act as risk factors ultimately contributing to an exacerbation of sickness symptoms, and should be considered as potential targets for therapeutic strategies.
我们旨在使用多元回归分析来确定脂多糖 (LPS) 在急性和晚期炎症期引起的身体不适症状的统计学预测变量。对接受静脉内 LPS 注射 (0.4 或 0.8ng/kg) 或安慰剂的 128 名健康志愿者的数据进行了汇总分析。使用经过验证的一般不良反应评估 (GASE) 问卷评估了急性 (注射后 0-6 小时) 和晚期 (注射后 6-24 小时) 期间的身体不适症状。接受 LPS 治疗的受试者报告的身体不适症状明显更多。急性阶段的身体症状与 LPS 引起的情绪障碍和白细胞介素 (IL)-6 增加有关，解释了 GASE 评分变化的 28.5%。在晚期，LPS 诱导的皮质醇和 IL-6 血浆浓度升高以及基线抑郁是显著的预测变量，解释了 38.5%的变化。在患有复发性或慢性炎症状态的患者中，这些因素可能作为最终导致疾病症状恶化的危险因素，应被视为潜在的治疗策略靶点。
